Loading
Biobeat
Biobeat makes wearable chest-patch and wrist devices that use proprietary photoplethysmography (PPG) sensors to measure blood pressure and other vital signs continuously and without a cuff. Data goes to a cloud platform with AI-based early-warning alerts. Customers include hospitals, long-term care facilities, cardiology and hypertension clinics, and pharma companies running clinical trials. It earns revenue from device sales and likely from platform subscriptions. In December 2025 it closed a $50M Series B led by Ally Bridge Group, OrbiMed and Elevage Medical to expand US commercialization. In January 2026 Kestra Medical Technologies took a $5M stake and signed a licensing and co-development deal. Headcount is reported at roughly 45–77 depending on the source.
Funding
Every round, secondary, debt facility or acquisition involving Biobeat that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—